Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - MRSA Skin Infection in Athletes : Article by

Quick Find
Authors & Editors
Introduction
Virulence
Prevalence
Clinical
Treatment
Prevention
Return to Play
References




Patient Education
Click here for patient education.


AUTHOR AND EDITOR INFORMATION

Section 1 of 9 Click here to go to the next section in this topic  

Author: John M Martinez, MD, Consulting Staff, Department of Primary Care Sports Medicine, Coastal Sports and Wellness Medical Group

John M Martinez is a member of the following medical societies: American Academy of Family Physicians, American College of Sports Medicine, and American Medical Society for Sports Medicine

Editors: Leslie Milne, MD, Assistant Clinical Instructor, Department of Emergency Medicine, Harvard University School of Medicine; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Russell D White, MD, Professor of Medicine, Department of Community and Family Medicine, University of Missouri-Kansas City School of Medicine, Truman Medical Center Lakewood; Jon B Whitehurst, MD, Clinical Instructor of Surgery, University of Illinois College of Medicine; Partner and Executive Board Member, Rockford Orthopedic Associates; Orthopedic Chairman, Rockford Memorial Hospital; Sherwin SW Ho, MD, Associate Professor, Department of Surgery, Section of Orthopedic Surgery and Rehabilitation Medicine, University of Chicago

Author and Editor Disclosure

Synonyms and related keywords: bacterial infection, methicillin-resistant Staphylococcus aureus, methicillin-resistant S aureus, community-acquired MRSA infection, CA-MRSA, hospital-acquired MRSA infection, HA-MRSA, nosocomial MRSA infection, athletic skin infection, staph infection, S aureus, mecA, SCCmec, Panton-Valentine leukocidin, PVL, USA300-0114

INTRODUCTION

Section 2 of 9 Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic  

Nosocomial infections of methicillin-resistant Staphylococcus aureus (MRSA) (ie, hospital-acquired MRSA [HA-MRSA]) have been reported since 1963.1 Community-acquired MRSA (CA-MRSA) infections are a more recent variant and are becoming more common in athletes2, 3, 4, 5, 6, 7, 8 and active individuals since the first reported cases in a high school wrestling team in 19939 and a British rugby club in 1998.10 CA-MRSA differs from HA-MRSA in its genetic makeup, increased pathogenicity, and susceptibility to antibiotic treatment.

The resistance of MRSA to beta-lactam antibiotics is due to the presence of the mecA gene sequence. The mecA gene produces transpeptidase PBP2a (penicillin-binding peptide) that decreases the bacterial affinity of the beta-lactam antibiotics. The mecA gene is a subset of a larger SCCmec gene that is responsible for the differences seen in HA-MRSA and CA-MRSA bacteria.11

Several variations of the SCCmec gene have been sequenced; SCCmec gene types I, II, and III are found in HA-MRSA, whereas CA-MRSA bacteria have the SCCmec type IV gene.12 The SCCmec gene types I-III are larger genes, and other portions of the gene provide resistance factors against other antibiotic classes. The type IV SCCmec gene is a small gene that has fewer of these additional resistance factors. This difference may explain the continued susceptibility of CA-MRSA compared with HA-MRSA to some oral antibiotics such as trimethoprim-sulfamethoxazole.

For excellent patient education resources, visit eMedicine's Blood and Lymphatic System Center; Infections Center; Cuts, Scrapes, Bruises, and Blisters Center; and Environmental Exposures and Injuries Center. Also, see eMedicine's patient education articles MRSA Infection, Sepsis (Blood Infection), Life-Threatening Skin Rashes, and Antibiotics.

Related eMedicine topics:
Cellulitis
Hospital-Acquired Infections
Staphylococcal Scalded Skin Syndrome [in the Dermatology section]
Staphylococcal Scalded Skin Syndrome [in the Emergency Medicine section]
Staphylococcus Aureus Infection
Wound Infection

Related Medscape topics:
Resource Center Emerging and Reemerging Infectious Diseases
Resource Center Patient Safety
Resource Center Sepsis
Resource Center Wound Management
CME Current Management Strategies Evaluated for Neonatal Community-Acquired Infection
CME Infection Control and Quarantine Issues (Slides With Transcript)
CME The New York Course 2007: Developments in Infectious Diseases—Community-Acquired Methicillin-Resistant Staphylococcus aureus Infections
CME Selecting Effective Treatment in the Antibiotic-Resistant Emergency Room Patient


VIRULENCE

Section 3 of 9 Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic  

CA-MRSA has been found in some cases to be a more virulent form compared with HA-MRSA. Up to 70% of CA-MRSA strains contain the Panton-Valentine leukocidin (PVL) virulence factor, including the most common form of CA-MRSA isolated from outbreaks in the United States.13


PREVALENCE

Section 4 of 9 Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic  

MRSA colonization

Studies have shown that approximately 25-30% of the population is colonized with methicillin-sensitive S aureus bacteria. Colonization is usually on the skin or in the nasal passages. One study demonstrated a 3% rate of MRSA nasal colonization in adult patients visiting an outpatient clinic for unrelated medical appointments.14 A similar study in an outpatient pediatric population detected MRSA colonization rates slightly above 1%.15

CA-MRSA infections in the general population

A prospective study in an Oakland, California, emergency department found that 51% of patients with a skin infection who presented for evaluation and treatment had positive culture results for MRSA; 99% of the MRSA infections contained the type IV SCCmec gene that is associated with the CA-MRSA strain, and 94% of MRSA isolates also contained the PVL gene.16

CA-MRSA outbreaks in athletes and other populations

Most publicized reports of CA-MRSA infection have been in college or professional football teams.2, 3, 4, 5, 6, 7, 8 However, outbreaks have also been reported in other sports, such as wrestling, rugby, and fencing. Other populations at risk for CA-MRSA outbreaks include military recruits, children in day care, prison inmates, homosexual men, and veterinarians, particularly those who have contact with farm animals, notably pigs.5, 17

Related Medscape topics:
CME Selecting Effective Treatment in the Antibiotic-Resistant Emergency Room Patient
Community-Acquired Methicillin-Resistant Staphylococcus aureus Infections: Changes in Practice Required?
Emergence of Methicillin-Resistant Staphylococcus aureus of Animal Origin in Humans
Update on Prevalence and Treatment of Methicillin-resistant Staphylococcus Aureus Infections


CLINICAL

Section 5 of 9 Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic  

Most CA-MRSA infections initially manifest as folliculitis or a similar soft-tissue or skin infection. Typically, the athlete may describe his or her presentation as an “infected pimple” or “insect bite.” Some CA-MRSA infections may have progressed to abscess formation. In other cases, the infection may manifest as a life-threatening illness, such as a rapidly progressing sepsis or pneumonia. 

The initial clinical examination usually reveals a limited area of redness, warmth, and swelling that is consistent with folliculitis. Occasionally, the patient may have swelling and pain in a joint. In more advanced cases, moderate to severe pain at the site of the infection may be reported; the pain may be due to soft-tissue necrosis from PVL activity.

Transmission

In severe cases of CA-MRSA infection, endocarditis, septicemia, necrotizing fasciitis, osteomyelitis, and multisystem organ failure, or death due to overwhelming sepsis may occur. Severe cases may progress extremely rapidly from the initial manifestation of an abscess.

The most common route of transmission of CA-MRSA is though an open wound, such as a superficial abrasion, or from contact with a CA-MRSA carrier. Other methods of transmission include poor hand washing, poor personal hygiene (eg, not showering after workouts), sharing personal items (eg, razors, towels, clothing), or a failure to properly clean and disinfect exercise and training equipment.

Related eMedicine topics:
Cellulitis
Pneumonia, Bacterial 
Pneumonia, Typical Bacterial 

Related Medscape topics:
Resource Center Sepsis
Resource Center Wound Management
CME Antibiotic Resistance: Highlights of the 17th European Congress of Clinical Microbiology and Infectious Diseases
CME CHEST 2007: Critical Care
CME From Principles to Practice: A Case-Based Approach to Treating Serious Skin Infections
CME Presentation, Prognosis, Treatment of Most Common Newborn Rashes Reviewed
CME The New York Course 2007: Developments in Infectious Diseases—Community-Acquired
CME What's New in Ventilator-Associated Pneumonia


TREATMENT

Section 6 of 9 Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic  

Outpatient treatment

The primary method of treatment for CA-MRSA skin and soft-tissue infections includes incision and drainage (I&D) of the abscess and therapy with appropriate antibiotics when indicated. Wound exudates should be cultured to accurately determine the causative organism and appropriate antibiotics for therapy.

The susceptibility of CA-MRSA is dependent on local resistance rates (US Centers for Disease Control and Prevention guidelines [see Antibiotic/Antimicrobial Resistance: Clinical Guidelines and CDC Surveillance Systems and Published Data, as well as Diseases Connected to Antibiotic Resistance: Methicillin-Resistant Staphylococcus aureus (MRSA)]). Typical treatment choices include oral antibiotics. 

  • Oral antibiotics
    • Trimethoprim-sulfamethoxazole (Bactrim DS; available as generic) twice daily, with or without rifampin, at 600 mg/d. Note: Rifampin is not a first-line drug for CA-MRSA, but this agent may be used in conjunction with other antibiotics for infections that do not respond to the initial treatment or for patients who experience recurrent infections.
    • Doxycycline at 100 mg twice daily
    • Clindamycin at 450 mg 3 times a day (96% sensitive): Resistance to clindamycin is increasing because of the inducible macrolide-lincosamide-streptogramin B (iMLSb) phenotype, which may result in cross-resistance to clindamycin.
    • Tetracycline
    • Minocycline
    • Not recommended due to resistance
      • Ciprofloxacin: This drug has a 33% sensitivity in some areas. Ciprofloxacin is not a good choice in pediatric patients because of concerns about its effect on growth plates.
      • Cephalexin (Keflex; MiddleBrook Pharmaceuticals, Inc, Germantown, Md)
    • Not recommended due to poor oral absorption
      • Oral vancomycin

Length of treatment

There are no well-controlled studies that demonstrate an optimal length of antibiotic treatment for CA-MRSA. 

Inpatient treatment

Treatment of moderate to severe CA-MRSA infections may require surgical debridement of the abscess, intravenous antibiotics, and hospitalization. The need for hospitalization should be made on a case-by-case basis.
  • Intravenous antibiotics
    • Vancomycin: Note that reports have described some intermediate vancomycin susceptibility in Japan, Texas, and New York.

      Some studies also indicate vancomycin treatment failure with MRSA bacteremia is associated with high mortality rates (1) when this agent is initiated after an inappropriate empiric antibiotic was used and (2) when vancomycin itself is the empiric agent in cases when the infective strain had a high vancomycin minimum inhibitory concentration (MIC).18, 19 Another study demonstrated previous antibiotic exposure is itself a risk for MRSA isolation.20 

    • Linezolid at 600 mg twice daily
    • Daptomycin at 4 mg/kg/d
    • Quinupristin-dalfopristin at 7.5 mg/kg every 8-12 hours

Investigational antibiotics

There are 2 anti-CA-MRSA beta-lactams, ceftaroline (cephalosporin) and ME1036 (carbapenem), that are under investigation. A preliminary study of susceptibility testing indicated that ceftaroline was 64-fold more potent than ceftriaxone, whereas ME1036 was >128-fold more potent than ceftriaxone.21 All isolates had the PVL genes and type IV SCCmec, and 67.8% showed the USA300-0114 strain, cloned via pulsed field gel electrophoresis (PFGE).

Another agent that is under study and that may hold potential for the prevention of catheter-associated infections, particularly against MRSA, is omiganan pentahydrochloride, a novel topical cationic peptide.22 

Recurrent infections

If an athlete has recurrent MRSA infections, suspect resistance to the previous antibiotic or nasal colonization, and send a nasal swab for culture. A different antibiotic may also be prescribed if the practitioner is concerned about a poor response to treatment. If the nasal swab culture is positive for CA-MRSA, then treat with mupirocin antibiotic ointment (Bactroban; GlaxoSmithKline, Research Triangle Park, NC) twice a day applied to the nares and oral rifampin at 300 mg twice daily for 7 days.

Related Medscape topics:
CME Selecting Effective Treatment in the Antibiotic-Resistant Emergency Room Patient
Clindamycin Susceptibility Rates in Local CA-MRSA Isolates at One Institution
Community-Acquired Methicillin-Resistant Staphylococcus aureus Infections: Changes in Practice Required?
News and Numbers From AHRQ - MRSA Kills 1 in 20 Hospital Patients Who Have the Infection


PREVENTION

Section 7 of 9 Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic  

Several key methods can be used for prevention of the spread of CA-MRSA infections. Because the most common source of infection is from close contact or from an open wound, preventive measures should focus on proper hygiene. Hand washing, using soap and water or antibacterial hand gels, should be encouraged by the infected patient and by individuals who come in direct contact with the patient. Additionally, open wounds and abrasions should be covered and protected.

Athletes should be educated and instructed to not share personal hygiene products such as razors or towels. Medical and training staff should continue to practice universal infectious disease protection measures. These personnel should ensure the proper disposal of bandages after dressing changes and the routine cleaning of equipment such as training tables, whirlpools, and exercise mats.

Related Medscape topics:
CME Infection Control and Quarantine Issues (Slides With Transcript)
Community-Acquired Methicillin-Resistant Staphylococcus aureus Infections: Changes in Practice Required?


RETURN TO PLAY

Section 8 of 9 Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic  

Athletes with mild cases of CA-MRSA infections may be allowed to return to athletic participation once an appropriate antibiotic treatment has commenced and the risk of transmission to other athletes has been significantly reduced or eliminated. Abrasions should be covered with a protective covering, and the athlete should be reevaluated daily for signs or symptoms of recurrence or worsening of the infection. The athlete and teammates should also be counseled about the need to avoid sharing towels, razors, or other personal items. Training staff should ensure proper disinfection of equipment and surfaces with which the infected athlete may come in contact, such as training tables, protective equipment, or wrestling mats, among other items.


REFERENCES

Section 9 of 9 Click here to go to the previous section in this topic Click here to go to the top of this page

  1. Jevons MP, Coe AW, Parker MT. Methicillin resistance in staphylococci. Lancet. Apr 27 1963;1:904-7. [Medline].
  2. Kurkowski C. CA-MRSA. The new sports pathogen. Orthop Nurs. Sep-Oct 2007;26(5):310-4; quiz 315-6. [Medline].
  3. Benjamin HJ, Nikore V, Takagishi J. Practical management: community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA): the latest sports epidemic. Clin J Sport Med. Sep 2007;17(5):393-7. [Medline].
  4. Sedgwick PE, Dexter WW, Smith CT. Bacterial dermatoses in sports. Clin Sports Med. Jul 2007;26(3):383-96. [Medline].
  5. Elston DM. Community-acquired methicillin-resistant Staphylococcus aureus. J Am Acad Dermatol. Jan 2007;56(1):1-16; quiz 17-20. [Medline].
  6. Nguyen DM, Mascola L, Brancoft E. Recurring methicillin-resistant Staphylococcus aureus infections in a football team. Emerg Infect Dis. Apr 2005;11(4):526-32. [Medline]. [Full Text].
  7. Begier EM, Frenette K, Barrett NL, et al. A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin Infect Dis. Nov 15 2004;39(10):1446-53. [Medline]. [Full Text].
  8. Centers for Disease Control and Prevention. Methicillin-resistant staphylococcus aureus infections among competitive sports participants--Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep. Aug 22 2003;52(33):793-5. [Medline]. [Full Text].
  9. Lindenmayer JM, Schoenfeld S, O'Grady R, Carney JK. Methicillin-resistant Staphylococcus aureus in a high school wrestling team and the surrounding community. Arch Intern Med. Apr 27 1998;158(8):895-9. [Medline]. [Full Text].
  10. Stacey AR, Endersby KE, Chan PC, Marples RR. An outbreak of methicillin resistant Staphylococcus aureus infection in a rugby football team. Br J Sports Med. Jun 1998;32(2):153-4. [Medline].
  11. Baba T, Takeuchi F, Kuroda M, et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet. May 25 2002;359(9320):1819-27. [Medline].
  12. Saďd-Salim B, Mathema B, Kreiswirth BN. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging pathogen. Infect Control Hosp Epidemiol. Jun 2003;24(6):451-5. [Medline]. [Full Text].
  13. Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med. Feb 3 2005;352(5):468-75. [Medline]. [Full Text].
  14. Jernigan JA, Pullen AL, Partin C, Jarvis WR. Prevalence of and risk factors for colonization with methicillin-resistant Staphylococcus aureus in an outpatient clinic population. Infect Control Hosp Epidemiol. Jun 2003;24(6):445-50. [Medline]. [Full Text].
  15. Nakamura MM, Rohling KL, Shashaty M, et al. Prevalence of methicillin-resistant Staphylococcus aureus nasal carriage in the community pediatric population. Pediatr Infect Dis J. Oct 2002;21(10):917-22. [Medline].
  16. Frazee BW, Lynn J, Charlebois ED, et al. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med. Mar 2005;45(3):311-20. [Medline].
  17. Wulf MW, Sřrum M, van Nes A, et al. Prevalence of methicillin-resistant Staphylococcus aureus among veterinarians: an international study. Clin Microbiol Infect. Jan 2008;14(1):29-34. [Medline].
  18. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. Jan 15 2008;46(2):193-200. [Medline].
  19. Moise PA, Smyth DS, El-Fawal N, et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. Jan 2008;61(1):85-90. [Medline]. [Full Text].
  20. Tacconelli E, De Angelis G, Cataldo MA, Pozzi E, Cauda R. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother. Jan 2008;61(1):26-38. [Medline].
  21. Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA). Antimicrob Agents Chemother. Jan 7 2008;epub ahead of print. [Medline].
  22. Fritsche TR, Rhomberg PR, Sader HS, Jones RN. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate and -resistant Staphylococcus aureus. Diagn Microbiol Infect Dis. Jan 4 2008;epub ahead of print. [Medline].
  23. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus skin infections among tattoo recipients--Ohio, Kentucky, and Vermont, 2004-2005. MMWR Morb Mortal Wkly Rep. Jun 23 2006;55(24):677-9. [Medline]. [Full Text].
  24. Ellington MJ, Yearwood L, Ganner M, East C, Kearns AM. Distribution of the ACME-arcA gene among methicillin-resistant Staphylococcus aureus from England and Wales. J Antimicrob Chemother. Jan 2008;61(1):73-7. [Medline].
  25. Feng Y, Chen CJ, Su LH, et al. Evolution and pathogenesis of Staphylococcus aureus: lessons learned from genotyping and comparative genomics. FEMS Microbiol Rev. Jan 2008;32(1):23-37. [Medline].
  26. Giavaresi G, Borsari V, Fini M, et al. Preliminary investigations on a new gentamicin and vancomycin-coated PMMA nail for the treatment of bone and intramedullary infections: An experimental study in the rabbit. J Orthop Res. Jan 9 2008;epub ahead of print. [Medline].
  27. Huang H, Cohen SH, King JH, et al. Injecting drug use and community-associated methicillin-resistant Staphylococcus aureus infection. Diagn Microbiol Infect Dis. Jan 4 2008;epub ahead of print. [Medline].
  28. Kato Y, Suzuki T, Ida T, et al. Microbiological and clinical study of methicillin-resistant Staphylococcus aureus (MRSA) carrying VraS mutation: changes in susceptibility to glycopeptides and clinical significance. Int J Antimicrob Agents. Jan 2008;31(1):64-70. [Medline].
  29. Kuroda M, Ohta T, Uchiyama I, et al. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet. Apr 21 2001;357(9264):1225-40. [Medline].
  30. Manzur A, Dominguez AM, Pujol M, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections: an emerging threat in Spain. Clin Microbiol Infect. Jan 11 2008;epub ahead of print. [Medline].
  31. Neoh HM, Cui L, Yuzawa H, et al. Mutated response regulator graR Is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob Agents Chemother. Jan 2008;52(1):45-53. [Medline].
  32. Ornskov D, Kolmos B, Bendix Horn P, et al. Screening for methicillin-resistant Staphylococcus aureus in clinical swabs using a high-throughput real-time PCR-based method. Clin Microbiol Infect. Jan 2008;14(1):22-8. [Medline].
  33. Tacconelli E. Methicillin-resistant Staphylococcus aureus: risk assessment and infection control policies. Clin Microbiol Infect. Jan 11 2008;epub ahead of print. [Medline].

MRSA Skin Infection in Athletes excerpt

Article Last Updated: Jan 16, 2008
Topic originally published: Jan 16, 2008